BidaskClub upgraded shares of United Therapeutics (NASDAQ:UTHR) from a buy rating to a strong-buy rating in a report released on Wednesday morning.

Other equities research analysts have also issued reports about the company. TheStreet upgraded United Therapeutics from a c+ rating to a b rating in a report on Thursday, August 16th. Wedbush set a $253.00 price target on United Therapeutics and gave the company a buy rating in a report on Wednesday, August 8th. Zacks Investment Research upgraded United Therapeutics from a hold rating to a buy rating and set a $127.00 price target for the company in a report on Saturday, July 7th. Standpoint Research upgraded United Therapeutics from a hold rating to a buy rating in a report on Friday, October 12th. Finally, HC Wainwright set a $95.00 price target on United Therapeutics and gave the company a hold rating in a report on Monday, August 13th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. United Therapeutics presently has an average rating of Hold and an average price target of $138.86.

Shares of United Therapeutics stock traded up $0.57 during trading on Wednesday, hitting $127.57. 4,237 shares of the stock traded hands, compared to its average volume of 378,138. The firm has a market cap of $5.57 billion, a price-to-earnings ratio of 11.57, a P/E/G ratio of 28.86 and a beta of 1.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.64 and a quick ratio of 4.35. United Therapeutics has a twelve month low of $100.57 and a twelve month high of $152.55.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.57 by $1.41. The business had revenue of $444.50 million during the quarter, compared to analyst estimates of $368.63 million. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The firm’s revenue was up .0% on a year-over-year basis. During the same period in the previous year, the company earned $4.37 EPS. As a group, equities research analysts predict that United Therapeutics will post 14.77 earnings per share for the current year.

In related news, Director Christopher Causey sold 810 shares of the firm’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $118.00, for a total value of $95,580.00. Following the transaction, the director now directly owns 3,925 shares of the company’s stock, valued at approximately $463,150. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard Giltner sold 3,240 shares of the firm’s stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total value of $419,191.20. The disclosure for this sale can be found here. Insiders sold a total of 4,860 shares of company stock worth $611,161 over the last three months. 8.20% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its position in United Therapeutics by 18.9% in the 2nd quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 33,400 shares of the biotechnology company’s stock worth $3,779,000 after buying an additional 5,300 shares during the period. Thompson Siegel & Walmsley LLC increased its position in United Therapeutics by 3.1% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 559,107 shares of the biotechnology company’s stock worth $63,263,000 after buying an additional 16,638 shares during the period. Glen Harbor Capital Management LLC increased its position in United Therapeutics by 26.0% in the 2nd quarter. Glen Harbor Capital Management LLC now owns 22,976 shares of the biotechnology company’s stock worth $2,600,000 after buying an additional 4,736 shares during the period. Neuburgh Advisers LLC increased its position in United Therapeutics by 26.0% in the 2nd quarter. Neuburgh Advisers LLC now owns 48,824 shares of the biotechnology company’s stock worth $5,525,000 after buying an additional 10,064 shares during the period. Finally, Fox Run Management L.L.C. increased its position in United Therapeutics by 85.2% in the 3rd quarter. Fox Run Management L.L.C. now owns 4,406 shares of the biotechnology company’s stock worth $563,000 after buying an additional 2,027 shares during the period. 95.83% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also: How to Use a Moving Average for TradingĀ 

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.